In this phase @b , open-label study with @ treatment subgroups , @ patients without cirrhosis who had not received treatment previously or who had not had a response to prior therapy were randomly assigned to a regimen of ABT-@ / r , combined with ABT-@ or ABT-@ or both , for @ , @ , or @ weeks and received at least one dose of therapy .